HER2 targeted agents, such as trastuzumab, lapatinib, T-DM1, and Pertuzumab, have all been successfully developed in BC, while all these agents failed to show benefit in GC except for trastuzumab [19–21]. The gene discussed is ERBB2; the disease is breast cancer.